RALEIGH, N.C., May 31, 2011 /PRNewswire/ -- Today, Campbell Alliance released the results of its Oncology National Commercial (ONC) Study, the latest in its Landmark Study series. A summary report of the study's findings is available at www.campbellalliance.com, and the firm is sharing a more in-depth presentation of the results with its clients by request.
The ONC Study explores the factors that have caused major changes in the oncology market over the past 10 years and evaluates how those factors will continue to shape the market during the next decade. It also provides recommendations on how pharmaceutical and biotech companies should manage the increasingly challenging oncology market environment.
To gather information for the study, Campbell Alliance interviewed decision makers from 9 of the world's top-20 pharmaceutical and biotech companies, a range of national and regional payer organizations, and several integrated delivery systems, as well as 10 oncology key opinion leaders and 20 community hematologists/oncologists.
According to Jeff Stewart, one of the study's authors, "We felt it was the right time to document how much oncology has changed over the past decade and take a look forward. In truth, the extent of change has been breathtaking. New therapies are only the beginning of the story. Oncologists have changed. Payers have changed. Sales forces have changed. Medicare has changed. Financial incentives have changed, and patients have changed. It's a different world, and it continues to evolve."
The study outlined 10 key trends that will shape the market for years to come. Five of the trends relate to product development, while the other five relate to commercial issues. The study's report indicates that these trends—when their effects are combined—are bringing about a "perfect storm" in oncolog
|SOURCE Campbell Alliance|
Copyright©2010 PR Newswire.
All rights reserved